We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Passage Bio Inc | NASDAQ:PASG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -1.56% | 1.26 | 1.22 | 1.39 | 1.30 | 1.23 | 1.28 | 81,552 | 01:00:00 |
From May 2022 to May 2024
By Michael Dabaie
Passage Bio Inc. said the U.S. Food and Drug Administration cleared its investigational new-drug application for PBML04 for the treatment of metachromatic leukodystrophy.
Shares were up 3.1% to $2.67 premarket Wednesday.
MLD is a rare, fatal pediatric lysosomal storage disease that currently has limited available treatment options, the company said.
"We are thrilled to have received IND clearance for our program in metachromatic leukodystrophy, marking our fourth IND clearance as a company and our third pediatric lysosomal storage disorder program to reach clinical development," Edgar Cale, interim chief executive officer, said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 08, 2022 08:18 ET (12:18 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Passage Bio Chart |
1 Month Passage Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
